Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Systemic Treatment With Everolimus for the Prevention of MACE After Bare Metal Stent Implantation
This study is currently recruiting participants.
Verified by German Heart Institute, January 2007
Sponsors and Collaborators: German Heart Institute
Novartis
Information provided by: German Heart Institute
ClinicalTrials.gov Identifier: NCT00426049
  Purpose

The purpose of the present study is to provide the first in-human safety and efficacy evaluations of systemic oral anti-proliferative Everolimus therapy compared to placebo in patients treated by bare metal stents for significant coronary artery disease. The aim is to reduce Major Adverse Cardiac Events (MACEs) including death, coronary artery bypass grafting (CABG) to the target vessel, Q-wave and non-Q-wave myocardial infarction, and target lesion revascularization within the first 6 months after intervention. Additionally safety and tolerability of Everolimus at the selected dose in this patient population will be analyzed.


Condition Intervention Phase
Coronary Artery Disease
Coronary Restenosis
Drug: Everolimus
Phase III

MedlinePlus related topics: Coronary Artery Disease
Drug Information available for: Everolimus
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: Monocenter, Double Blinded, Prospective, Randomized Placebo Controlled Study Investigating Prevention of Major Adverse Cardiac Events (MACEs) Within 6 Months by Systemic Treatment With Everolimus After Coronary Intervention With Bare Metal Stents in Patients With Significant Coronary Artery Disease

Further study details as provided by German Heart Institute:

Primary Outcome Measures:
  • Major adverse cardiac events (MACEs)within 6 months

Secondary Outcome Measures:
  • MACEs within 30 days
  • Quantitative angiographic observations within the vessel after 6 months
  • TLR and TVR after 6 months
  • Drug safety and tolerability for 6 months

Estimated Enrollment: 484
Study Start Date: October 2006
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males or females, aged >18 years.
  2. Patients with coronary artery disease who are scheduled for coronary intervention with bare metal stent placement for treatment of de novo or first restenosis in a native coronary artery.
  3. Target lesion must be in a native coronary vessel of 2.25 – 4.0 mm size.
  4. Target lesion has to be of less than or equal to 25 mm length.
  5. Tandem lesion may be included as long as:

    • overall length is less than or equal to 25 mm
    • tandem lesion will be treated with one stent and counted as one lesion.

Exclusion Criteria:

The following exclusion criteria must not be present at Baseline visit 1 (BL1, Screening visit prior to coronary intervention). If an exclusion criterion occurred afterwards, e.g., during the coronary intervention, the patient must be excluded from the study.

  1. Target lesion has a reference vessel size of less than 2.25 or more than 4.0 mm diameter.
  2. Target lesion is a total occlusion or located at a bifurcation.
  3. Treatment affords implantation of more than one stent per treated lesion.
  4. Target lesion was already treated by brachytherapy.
  5. Target lesion has one or more of the following criteria:

    • Left main lesion
    • Ostial lesion of the RCA
    • Located at less than 2 mm after the origin of the LAD or RCX.

Other protocol defined inclusion/exclusion criteria may apply.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00426049

Contacts
Contact: Eckart Fleck, Professor +49-(0)30-4593 ext 2400 fleck@dhzb.de

Locations
Germany
German Heart Institute Berlin Recruiting
Berlin, Germany, 13353
Principal Investigator: Eckart Fleck, Professor            
Sponsors and Collaborators
German Heart Institute
Novartis
Investigators
Principal Investigator: Eckart Fleck, Professor German Heart Institute Berlin
  More Information

Study ID Numbers: CRAD001ADE07
Study First Received: January 23, 2007
Last Updated: January 23, 2007
ClinicalTrials.gov Identifier: NCT00426049  
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by German Heart Institute:
Coronary artery disease
Stents
Immunosuppressive Agents
Coronary restenosis
Safety

Study placed in the following topic categories:
Everolimus
Arterial Occlusive Diseases
Coronary Disease
Heart Diseases
Myocardial Ischemia
Vascular Diseases
Constriction, Pathologic
Arteriosclerosis
Ischemia
Coronary Stenosis
Coronary Restenosis
Coronary Artery Disease

Additional relevant MeSH terms:
Immunologic Factors
Physiological Effects of Drugs
Cardiovascular Diseases
Immunosuppressive Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 13, 2009